Меню
Идёт набор NCT06963177

A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain

Фаза II С лечением Endometriosis-related Pain

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: GenSci048, Placebo.
Кому может быть актуально
Состояния в реестре: Endometriosis-related Pain. Базовые параметры: 18 лет — 49 лет · Женщины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain

Обзор

This study is designed to evaluate the safety and efficacy of GenSci048 for moderate to severe endometriosis-associated pain treatment.

Вмешательства

  • Препарат GenSci048
    Administered SC.
  • Препарат Placebo
    Administered SC.

Первичные конечные точки

  • Change of dysmenorrhea (DYS) measured by Numeric Rating Scale (NRS) [Срок оценки: baseline, week 24]
  • Change of non-menstrual pelvic pain (NMPP) measured by Numeric Rating Scale (NRS) [Срок оценки: baseline, week 24]
Вторичные конечные точки (4)
  • Change of DYS, NMPP, and dyspareunia (DYSP) measured by Numeric Rating Scale (NRS). The NRS for overall endometriosis-associated pain ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome. [Срок оценки: 52 weeks]
  • Permitted rescue medication use. [Срок оценки: 52 weeks]
  • Patient Global Impression of Change, Patient Global Impression of Change (minimum 1, maximum 7, higher score mean a worse outcome). [Срок оценки: Week 12、Week 24、Week 52]
  • Adverse Event [Срок оценки: up to approximately 56 weeks]

Критерии участия

Критерии включения

  • Pre-menopausal female participants, between 18 and 49 years of age, inclusive, at the time of signing informed consent.
  • Participants must have a diagnosis of endometriosis within 10 years before screening.
  • Have moderate to severe endometrial related pain.
  • Have at least one regular, natural menstrual cycles (ranging from 21 to 35 days (inclusive)) before and during the screening period.
  • Agree to switch from her usual analgesic medication to only that which is permitted in the study from the screening period to the end of treatment and agree to stop using other treatments for endometriosis.
  • Agree to use non-hormonal contraception from the time of signing the informed consent until 4 weeks after the last dose of the study medication.

Критерии исключения

  • Participants who have previously received hysterectomy and/or bilateral oophorectomy, or plan to undergo these procedures during the study period.
  • Participants who suffer from chronic pelvic and/or non-pelvic pain that is not caused by EM and require chronic analgesia or other chronic treatment, which is expected to affect the assessment of EAP.
  • Pelvic ultrasound screening indicating a need for surgery or suspicion of malignancy.
  • Participants with abnormal and undiagnosed vaginal and/or uterine bleeding within 3 months prior to screening.
  • Participants who plan to schedule elective surgery during the study; or those who have had a surgery within 4 months prior to screening and need ongoing pain management.
  • History of severe depression or post-traumatic stress disorder within the two years prior to screening, or history of any other severe mental disorder at any time.
  • History of drug or alcohol abuse within the six months prior to screening.
  • Participants who have participated in any other interventional clinical trial (including clinical trials of drugs and devices) within 1 month prior to screening.
  • Have used a prohibited long-acting anesthetic or immediate-release anesthetic for more than 2 consecutive weeks for the treatment of endometriosis associated pain in the 6 months prior to screening.
  • Participant is pregnant, breast feeding, or planning a pregnancy.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Четверное слепое
Основная цель
Лечение

Центры проведения

Китай · 1 центр
  • Peking University First Hospital — Пекин

Идентификаторы

NCT: NCT06963177 · GenSci048-205

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗